📊 NTRA Key Takeaways
Is NTRA a Good Investment? Thesis Analysis
Natera demonstrates strong revenue growth (35.9% YoY) and healthy liquidity position with solid free cash flow generation ($109.1M), indicating operational momentum in a growing medical diagnostics market. However, persistent operating losses (-13.4% margin) and negative profitability despite scale suggest the company is still in an expensive growth phase with significant path-to-profitability questions unresolved.
Why Buy NTRA? Key Strengths
- Strong revenue growth at 35.9% YoY showing market traction and demand expansion
- Healthy free cash flow of $109.1M despite operating losses demonstrates underlying operational efficiency
- Excellent liquidity position with 3.39x current ratio and $1.1B cash providing runway for continued investment
- Low leverage with 0.17x debt-to-equity ratio providing financial flexibility
- Positive gross margin of 31.4% indicating pricing power and core business viability
NTRA Investment Risks to Consider
- Persistent operating losses of -$309.9M and negative net margin of -9.0% despite $2.3B revenue scale raise profitability sustainability questions
- Negative return on equity (-12.2%) and return on assets (-8.7%) indicate capital is not being deployed efficiently
- High insider activity (54 Form 4 filings in 90 days) may signal uncertainty among management regarding company direction
- Operating margin deterioration suggests operating expenses growing faster than revenue despite scale advantages
- Interest coverage ratio of -76.2x indicates inability to cover debt service from operations, relying on cash reserves
Key Metrics to Watch
- Path to operating profitability and quarterly operating margin trend
- Free cash flow sustainability and burn rate relative to cash reserves
- Operating expense ratio as percentage of revenue and evidence of operating leverage
- Gross margin stability and any pricing pressure in medical diagnostics market
- Insider transaction patterns and aggregate share count changes
NTRA Financial Metrics
💡 AI Analyst Insight
The relatively thin 4.7% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.39x current ratio provides a solid financial cushion.
NTRA Profitability Ratios
NTRA vs Healthcare Sector
How Natera, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NTRA Overvalued or Undervalued?
Based on fundamental analysis, Natera, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NTRA Balance Sheet & Liquidity
NTRA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Natera, Inc.'s revenue has grown significantly by 269% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.78 indicates the company is currently unprofitable.
NTRA Growth Metrics (YoY)
NTRA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $439.8M | -$31.6M | $-0.26 |
| Q2 2025 | $413.4M | -$37.5M | $-0.30 |
| Q1 2025 | $367.7M | -$66.9M | $-0.50 |
| Q3 2024 | $268.3M | -$31.6M | $-0.26 |
| Q2 2024 | $261.4M | -$37.5M | $-0.30 |
| Q1 2024 | $241.8M | -$67.6M | $-0.56 |
| Q3 2023 | $210.6M | -$109.0M | $-0.95 |
| Q2 2023 | $198.2M | -$110.8M | $-0.97 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NTRA Capital Allocation
NTRA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Natera, Inc. (CIK: 0001604821)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_090401.xml | View → |
| Apr 1, 2026 | 8-K | tm2610771d1_8k.htm | View → |
| Mar 20, 2026 | 4 | xslF345X06/form4-03202026_090301.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_090301.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_090301.xml | View → |
❓ Frequently Asked Questions about NTRA
What is the AI rating for NTRA?
Natera, Inc. (NTRA) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NTRA's key strengths?
Claude: Strong revenue growth at 35.9% YoY showing market traction and demand expansion. Healthy free cash flow of $109.1M despite operating losses demonstrates underlying operational efficiency.
What are the risks of investing in NTRA?
Claude: Persistent operating losses of -$309.9M and negative net margin of -9.0% despite $2.3B revenue scale raise profitability sustainability questions. Negative return on equity (-12.2%) and return on assets (-8.7%) indicate capital is not being deployed efficiently.
What is NTRA's revenue and growth?
Natera, Inc. reported revenue of $2.3B.
Does NTRA pay dividends?
Natera, Inc. does not currently pay dividends.
Where can I find NTRA SEC filings?
Official SEC filings for Natera, Inc. (CIK: 0001604821) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NTRA's EPS?
Natera, Inc. has a diluted EPS of $-1.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NTRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Natera, Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NTRA stock overvalued or undervalued?
Valuation metrics for NTRA: ROE of -12.2% (sector avg: 15%), net margin of -9.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NTRA stock in 2026?
Our dual AI analysis gives Natera, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NTRA's free cash flow?
Natera, Inc.'s operating cash flow is $215.3M, with capital expenditures of $106.2M. FCF margin is 4.7%.
How does NTRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9.0% (avg: 12%), ROE -12.2% (avg: 15%), current ratio 3.39 (avg: 2).